Literature DB >> 12791711

Preventing and treating influenza.

Klaus Stöhr.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12791711      PMCID： PMC1126107          DOI： 10.1136/bmj.326.7401.1223

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Economic evaluation of strategies for the control and management of influenza in Europe.

Authors:  P A Scuffham; P A West
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

Review 2.  Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.

Authors:  Nicola J Cooper; Alexander J Sutton; Keith R Abrams; Allan Wailoo; David Turner; Karl G Nicholson
Journal:  BMJ       Date:  2003-06-07

3.  Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Authors:  J McKimm-Breschkin; T Trivedi; A Hampson; A Hay; A Klimov; M Tashiro; F Hayden; M Zambon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
  3 in total
  24 in total

1.  Neuraminidase inhibitors for influenza A and B: PROSE may be as useful as POEMs.

Authors:  Nick C Bradley
Journal:  BMJ       Date:  2003-07-12

2.  Tackling the next influenza pandemic.

Authors:  Ran D Balicer; Michael Huerta; Itamar Grotto
Journal:  BMJ       Date:  2004-06-12

3.  The effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesis.

Authors:  Julie L McAuley; Kelly Zhang; Jonathan A McCullers
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

4.  The Influenza Virus Protein PB1-F2 Increases Viral Pathogenesis through Neutrophil Recruitment and NK Cells Inhibition.

Authors:  Aurore Vidy; Pauline Maisonnasse; Bruno Da Costa; Bernard Delmas; Christophe Chevalier; Ronan Le Goffic
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

5.  Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections.

Authors:  Laura Haynes; Frank M Szaba; Sheri M Eaton; Lawrence W Kummer; Paula A Lanthier; Ashlee H Petell; Debra K Duso; Deyan Luo; Jr-Shiuan Lin; Julie S Lefebvre; Troy D Randall; Lawrence L Johnson; Jacob E Kohlmeier; David L Woodland; Stephen T Smiley
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

6.  Discovery of Novel Neuraminidase Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.

Authors:  Rao Yu; Li Ping Cheng; Meng Li; Wan Pang
Journal:  ACS Med Chem Lett       Date:  2019-11-25       Impact factor: 4.345

7.  Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.

Authors:  Victor C Huber; Raelene M McKeon; Martha N Brackin; Laura A Miller; Rachael Keating; Scott A Brown; Natalia Makarova; Daniel R Perez; Gene H Macdonald; Jonathan A McCullers
Journal:  Clin Vaccine Immunol       Date:  2006-09

Review 8.  An update on the prevention of influenza in children and adolescents.

Authors:  Ulrich Heininger
Journal:  Eur J Pediatr       Date:  2003-10-21       Impact factor: 3.183

9.  Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.

Authors:  Min-Chul Kim; Yu-Na Lee; Hye Suk Hwang; Young-Tae Lee; Eun-Ju Ko; Yu-Jin Jung; Min Kyoung Cho; Yu-Jin Kim; Jong Seok Lee; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

10.  The platelet activating factor receptor is not required for exacerbation of bacterial pneumonia following influenza.

Authors:  Jonathan A McCullers; Amy R Iverson; Raelene McKeon; Peter J Murray
Journal:  Scand J Infect Dis       Date:  2007-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.